Table 7. Acceptability of a novel rapid sputum-based molecular assay and a novel serological assay.a.
| Acceptability | Total | Income level of the countries (World Bank classification) | p | |||
|---|---|---|---|---|---|---|
| High | Upper middle | Lower middle | Low | |||
| Novel rapid molecular assay (prototype of a sputum-based assay) | ||||||
| Not acceptable | 38 (5.26) | 9 (4.71) | 12 (4.56) | 7 (4.07) | 10 (10.42) | 0.0825 |
| Acceptable | 622b (86.03) | 157 (82.20) | 235 (89.35) | 153 (88.95) | 76 (79.17) | |
| Do not know | 63 (8.71) | 25 (13.09) | 16 (6.08) | 12 (6.98) | 10 (10.42) | |
| Total | 723b | 191 | 263 | 172 | 96 | |
| Acceptable only if fully validated | 355 (57.07) | 70 (44.59) | 140 (59.57) | 101 (66.01) | 44 (57.89) | 0.0025 |
| Acceptable even if still being validatedc | 227 (36.50) | 78 (49.68) | 81 (34.47) | 41 (26.80) | 27 (35.53) | |
| Acceptable (manufacturer’s assurance sufficient) | 40b (6.43) | 9 (5.73) | 14 (5.96) | 11 (7.19) | 5 (6.58) | |
| Novel serological assay (prototype of a biomarker-based triage test) | ||||||
| Not acceptable | 61 (8.44) | 20 (10.47) | 19 (7.22) | 17 (9.88) | 5 (5.21) | 0.0383 |
| Acceptable | 591b (81.74) | 141 (73.82) | 227 (86.31) | 140 (81.40) | 82 (85.42) | |
| Do not know | 71 (9.82) | 30 (15.71) | 17 (6.46) | 15 (8.72) | 9 (9.38) | |
| Total | 723b | 191 | 263 | 172 | 96 | |
| Acceptable only if fully validated and in line with WHO indications | 378b (63.96) | 78 (55.32) | 144 (63.44) | 100 (71.43) | 55 (67.07) | 0.1250 |
| Acceptable even if still being validated,c provided it was developed in line with WHO indications | 193 (32.66) | 59 (41.84) | 73 (32.16) | 36 (25.71) | 25 (30.49) | |
| Acceptable (manufacturer’s assurance sufficient) | 20 (3.38) | 4 (2.84) | 10 (4.41) | 4 (2.86) | 2 (2.44) | |
a
Values expressed as n (%), except where otherwise indicated. bIncludes one respondent working in a country that could not be classified according to the World Bank classification. cIf sufficiently independent peer-reviewed data are available.